...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Anticancer Research: International Journal of Cancer Research and Treatment >Prognostic Significance of Serum CEA for Non-small Cell Lung Cancer Patients Receiving Stereotactic Body Radiotherapy
【24h】

Prognostic Significance of Serum CEA for Non-small Cell Lung Cancer Patients Receiving Stereotactic Body Radiotherapy

机译：非小细胞肺癌患者血清CEA接受立体定向体放射治疗的预后意义

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Background/Aim: To examine the prognostic significance of serum carcinoembryonic antigen (CEA) for stage I non-small cell lung cancer (NSCLC) treated with stereotactic body radiotherapy (SBRT). Patients and Methods: In total, 129 stage I NSCLC patients were analyzed and divided into two groups: CEA-High (CEA> 5 ng/ml) and CEA-Low (CEA <= 5 ng/ml). Results: Median follow-up time was 38 months. Overall survival was not significantly different between CEA-High (n= 47) and CEA-Low (n= 82) patients (57% vs. 63% at 3 years; p= 0.39), although progression-free survival (PFS) was significantly worse in CEA-High patients (31% vs. 51% at 3 years; p= 0.01). Larger tumor size and high CEA level were independent prognostic factors for worse PFS. Failure pattern analysis showed that regional node or distant recurrence was more common in CEA-High patients (47%) than in CEA-Low patients (29%). Conclusion: Patients with CEA-High stage I NSCLC have a higher risk of regional or systemic relapse and should be followed-up carefully.
机译：背景/目的：检查用立体定向体放射治疗（SBRT）治疗的I阶段非小细胞肺癌（NSCLC）血清癌丙烯抗原（CEA）的预后意义。患者和方法：总共分析了129阶段，分为两组：CEA-HIGH（CEA> 5 ng / ml）和CEA-LOW（CEA <= 5 ng / mL）。结果：中位后续时间为38个月。 CEA-HIGH（N = 47）和CEA-LOW（n = 82）患者（3年内57％vs.63％）之间的总体存活率没有显着差异;虽然无进展生存（PFS）是在CEA-High患者中显着更差（3年31％，3岁; P = 0.01）。肿瘤大小和高CEA水平是较差的PFS的独立预后因素。失败模式分析表明，在CEA-High患者（47％）中，区域节点或远程复发比在CEA-LOW患者（29％）中更常见。结论：CEA高阶段I NSCLC患者具有更高的区域或全身复发风险，应仔细随访。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号